Price (delayed)
$41.56
Market cap
$3.09B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.89
Enterprise value
$3.01B
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks
There are no recent dividends present for SWTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.